Search is Powered by Google
Cancer / Oncology News

Racial Disparities Persist In Cancer Care

Main Category: Cancer / Oncology
Article Date: 08 Jan 2008 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

A new study finds that, despite efforts in the last decade to mitigate cancer treatment disparities, black patients are significantly less likely than white patients to receive therapy for various types of cancer. The authors of the study conclude that efforts to close treatment gaps initiated in the 1990s appear to have had little impact. The report appears in the February 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society. Research that revealed racial disparities in cancer care began to appear in the early and 1990s, leading to greater attention and investment in ensuring access to care to all individuals. However, little is known about whether those efforts have led to any reduction in cancer treatment disparities.

To find out, Cary P. Gross, M.D. of the Yale University School of Medicine in New Haven, Conn. and colleagues mined the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to evaluate cancer care received by Medicare beneficiaries diagnosed with breast, colorectal, lung or prostate cancer from 1992 through 2002. After identifying therapies for which racial disparities had been previously reported, the investigators determined whether there had been any changes in care for the over-all Medicare population or for white and black patients considered separately. A total of 7,775 colon, 1,745 rectal, 11,207 lung, 40,457 breast, and 82,238 prostate cancer cases were evaluated.

In their analysis, the researchers found that for both black and white patients, there was little or no improvement in the proportion of patients receiving therapy for most cancers. In addition, there was no decrease in the magnitude of racial disparities between 1992 and 2002. Black patients were significantly less likely than white patients to receive therapy for cancers of the lung, breast, colon, and prostate. Racial disparities persisted even after limiting the analysis to patients who had access to a physician prior to their cancer diagnosis.

The findings suggest that there has been little improvement in the overall proportion of Medicare beneficiaries receiving cancer care. They also reveal that racial disparities have not lessened. "Efforts in the last decade to mitigate cancer therapy disparities appear to have been unsuccessful," the authors conclude.

In moving forward, "future efforts to reduce disparities should be incorporated into a larger quality improvement framework," the authors note.

Article: "Racial Disparities in Cancer Therapy: Did the Gap Narrow Between 1992 and 2002?" Cary P. Gross, Benjamin D. Smith, Elizabeth Wolf, and Martin Andersen. CANCER; Published Online: January 7, 2008 (DOI: 10.1002/cncr.23228); Print Issue Date: February 15, 2008.

American Cancer Society




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...